[Cyclosporin in autoimmune diseases]

Area of Science:

• Immunology
• Pharmacology
• Clinical Medicine

Background:

• Cyclosporine (Sandimmun) is a well-established immunosuppressant in organ transplantation.
• Recent trials have explored its efficacy in a broader range of immune-related diseases.

Purpose of the Study:

• To evaluate the efficacy and safety of cyclosporine in various non-transplant immune conditions.
• To assess the benefit-risk ratio of cyclosporine therapy in different patient populations.

Main Methods:

• Prospective controlled trials were conducted across multiple clinical entities.
• Data from these trials were analyzed to determine treatment efficacy and identify side effects.

Main Results:

• Proven efficacy in endogenous uveitis, rheumatoid arthritis, Sjögren's syndrome, myasthenia gravis, psoriasis, and Crohn's disease.
• Beneficial effects observed in aplastic anemia, glomerulonephritis (proteinuria reduction), and multiple sclerosis.
• Limited or unfavorable benefit-risk ratio in multiple sclerosis, amyotrophic lateral sclerosis, and primary biliary cirrhosis.
• Potential in insulin-dependent diabetes and Graves' ophthalmopathy when combined with prednisone.
• Common side effects include renal dysfunction, hypertension, gout, tremor, gingival hyperplasia, and hypertrichosis, generally manageable.

Conclusions:

• Cyclosporine is an effective treatment for several immune diseases beyond organ transplantation.
• Careful patient selection and dosage management are crucial to balance efficacy and side effects.
• Further research is warranted for conditions like primary biliary cirrhosis and early-stage diabetes.